Ionis Pharmaceuticals (IONS) Research & Development (2016 - 2025)
Ionis Pharmaceuticals (IONS) has 17 years of Research & Development data on record, last reported at $279.6 million in Q4 2025.
- For Q4 2025, Research & Development rose 13.91% year-over-year to $279.6 million; the TTM value through Dec 2025 reached $915.6 million, up 1.56%, while the annual FY2025 figure was $915.6 million, 1.56% up from the prior year.
- Research & Development reached $279.6 million in Q4 2025 per IONS's latest filing, up from $217.8 million in the prior quarter.
- Across five years, Research & Development topped out at $279.6 million in Q4 2025 and bottomed at -$444.9 million in Q4 2022.
- Average Research & Development over 5 years is $141.6 million, with a median of $207.5 million recorded in 2024.
- Peak YoY movement for Research & Development: tumbled 351.25% in 2021, then surged 157.67% in 2023.
- A 5-year view of Research & Development shows it stood at -$429.1 million in 2021, then decreased by 3.68% to -$444.9 million in 2022, then soared by 157.67% to $256.6 million in 2023, then dropped by 4.31% to $245.5 million in 2024, then rose by 13.91% to $279.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Research & Development were $279.6 million in Q4 2025, $217.8 million in Q3 2025, and $217.5 million in Q2 2025.